ENVALITH
株式会社パイオラックス logo

PIOLAX,INC.

5988・Prime Market・Metal Products

Official website
株式会社パイオラックス logo
PIOLAX,INC.5988

Business

Piolax is a precision spring and fastener manufacturer founded in 1933, with a core strength in composite molding technology spanning both metal and resin. Its mainstay Automotive-related, etc. segment (approximately 91% of consolidated net sales) manufactures Industrial Fasteners, Precision Springs, Small Unit Parts, fluid control components, and other products, supplying domestic and overseas automakers including Nissan Motor. The company has built a global manufacturing network with plants in the United States, the United Kingdom, South Korea, Thailand, China, India, Mexico, and Indonesia. In the Medical Devices segment, it manufactures and sells minimally invasive treatment devices, expanding its product range from IVR (Interventional Radiology) Devices into Endoscopic Treatment Devices and Orthopedic Treatment Devices. The company is listed on the Prime Market of the Tokyo Stock Exchange.

Business Model

The company focuses primarily on supplying parts to automakers, granting technology license agreements (receiving a certain percentage of sales as technical guidance fees) to domestic and overseas manufacturing subsidiaries, while establishing local production and local sales systems to secure earnings while diversifying foreign exchange risk. In the Medical Devices business, the company applies metal processing technology cultivated through automotive parts development to manufacture and sell minimally invasive treatment devices. Under a cooperation agreement with France's A.RAYMOND, the company also engages in sales, technical, and production/sales cooperation for fastener products.

Company Strengths

Since its founding in 1933, the company has expanded its technological domain from Precision Springs to resin fasteners, accumulating composite molding technology proficient in both metals and resins. This is utilized in the development and mass production of high-value-added products for electrification, such as busbars and ADAS-related parts, forming a technological asset that competitors find difficult to replicate in a short period. R&D expenses amounted to ¥744 million in FY2026 (ending March 2026).

The company has manufacturing subsidiaries in the US, UK, South Korea, Thailand, China (2 sites), India, Mexico, and Indonesia, building a local production system with technology license agreements granted to each subsidiary. In India, a second plant is under construction in the Pune area, advancing production capacity expansion. The company aims to optimize its supply system and maintain cost competitiveness through local production and local procurement.

Piolax Medical Devices Corporation, established in 1999, manufactures and sells minimally invasive treatment devices. Sales for FY2026 (ending March 2026) reached ¥5,274 million (up 2.0% year on year), continuing to grow even as Automotive-related, etc. saw declining sales. Product pipeline expansion is progressing, including obtaining Japan's first approval for a bioabsorbable esophageal stent and filing an application for approval of a new product applying vascular embolization coil technology.

ENVALITH's Perspective

In FY2026 (ending March 2026), production cuts by Japanese automakers dealt a direct blow, with net sales of ¥62,045 million (down 2.1% year on year), operating profit of ¥1,470 million (down 38.3%), and a net loss attributable to owners of the parent of ¥21 million, marking a second consecutive year of sharp profit decline and the company's first net loss ever. External factors—sluggish sales by Japanese makers in the Chinese market, the rapid shift to EVs, and stagnation in the US market—compounded one another, once again highlighting the structural vulnerability stemming from dependence on Japanese manufacturers. While efforts to expand sales to non-Japanese customers continue, their contribution to earnings remains limited.

In FY2026 (ending March 2026), the company recorded an impairment loss of ¥423 million (related to subsidiaries in China and the UK) and an extraordinary loss of ¥325 million for early retirement incentive payments, leaving profit before income taxes at just ¥763 million. Cash flow from operating activities fell 63.0% year on year to ¥3,003 million, and after deducting capital expenditures for property, plant and equipment of ¥9,565 million, free cash flow was negative at ¥4,557 million. The large-scale share buyback (¥23,979 million) was funded through short-term borrowings (¥24,171 million), causing the equity ratio to fall sharply from 85.8% to 63.9%—a change in financial structure that warrants attention.

The consolidated earnings forecast for FY2027 (ending March 2027) projects net sales of ¥63,000 million (up 1.5% year on year), operating profit of ¥1,500 million (up 2.0%), and net income of ¥700 million, indicating a modest recovery. The assumed exchange rate is 1 USD = ¥150. However, external factors such as additional US tariffs and rising crude oil prices amid Middle East tensions are not factored into the forecast, leaving downside risk. The dividend payout ratio is projected at an extremely high 335.2% for FY2027 (ending March 2027), raising questions about the company's ability to sustain dividends should the earnings recovery be delayed.

Growth Strategy

Driving transformation through four pillars: expanded sales to non-Japanese OEMs, high-value-added products, expansion of the Medical Devices segment, and improved capital efficiency

To reduce dependence risk on Japanese automakers, the company continues to promote sales expansion activities targeting non-Japanese OEMs in the US, Europe, and China. In FY2026 (ending March 2026), results were affected by production cuts among Japanese automakers, but global sales expansion activities continued, with sales by location in North America and Asia maintaining a certain level.

The group as a whole is promoting profitability improvement activities. In FY2026 (ending March 2026), the company recorded ¥325 million in early retirement incentive payments and implemented structural reforms. Cost of sales decreased by ¥763 million year on year to ¥48,316 million, but due to an increase in selling, general and administrative expenses, the operating margin remained at 2.4%. The target for FY2027 (ending March 2027) is operating profit of ¥1,500 million (operating margin of 2.4%).

Piolax Medical Devices Corporation is actively promoting sales expansion of IVR (Interventional Radiology) Devices, Endoscopic Treatment Devices, and Orthopedic Treatment Devices. In FY2026 (ending March 2026), net sales grew to ¥5,274 million (up 2.0% year on year), maintaining growth, but operating profit declined to ¥278 million (down 15.0% year on year) due to increased labor costs and other factors. The company aims for medium- to long-term growth, leveraging the external tailwind of an aging society.

Through restraining the accumulation of equity capital and thorough group cash management, the company maintains a policy of a consolidated dividend payout ratio of 100% and an annual dividend of ¥92 or more. In FY2026 (ending March 2026), the company conducted share buybacks of ¥23,979 million and maintained an annual dividend of ¥92. For FY2027 (ending March 2027), an annual dividend of ¥92 (a forecast payout ratio of 335.2%) is also planned.

Last updated: July 19, 2026